The Bochum Optimizing Clopidogrel-Aspirin Therapy and MORTality Study (BOCLA-Mort)

Comparing standard treatment versus optimized antiplatelet therapy and outcomes measures.

Completed

Looking for future studies?

Key information

Conditions

Coronary Artery Disease Acute Coronary Syndrome Arterial Occlusive Diseases Arteriosclerosis Cardiovascular Diseases Coronary Disease Heart Diseases Myocardial Ischemia Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cardiovascular Center, Ruhr-University Bochum

Bochum, North Rhine-Westphalia, D-44791, Germany

About this study

The study is aimed to evaluate if optimized antiplatelet treatment using a test and treat algorithm (with whole blood aggregometry) is able to improve clinical outcome of patients compared to standard treatment without platelet function testing.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

coronary stent implantation

Exclusion criteria

no consent

Treatment and study plan

Primary outcomes

Adverse cardiac events (MACE: mortality,rehospitalisation,myocardial infarction)

Time frame: Follow up for up to 12 months (retrospective analysis)

MACE-rate

Sponsors and collaborators

Lead sponsor

Ruhr University of Bochum

Other

Registry information

Official study title

Optimized Antiplatelet Therapy With Aspirin and Clopidogrel Improves Mortality Compared to Standard Treatment.

Acronym: BOCLA-Mort

Important dates

Study start: 2009
Primary completion: 2013
Study completion: 2013
First posted: Feb 22, 2013
Registry last updated: Feb 26, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed